Suppr超能文献

替代医学作为炎症性肠病的新兴疗法。

Alternative medicines as emerging therapies for inflammatory bowel diseases.

机构信息

Department of Pathology, Microbiology and Immunology, School of Medicine, University of South Carolina, Columbia, South Carolina 29208, USA.

出版信息

Int Rev Immunol. 2012 Feb;31(1):66-84. doi: 10.3109/08830185.2011.642909.

Abstract

Inflammatory bowel disease (IBD) can be divided into two major categories, ulcerative colitis (UC) and Crohn disease (CD). While the main cause(s) of IBD remain unknown, a number of interventional and preventive strategies have been proposed for use against CD and UC. Many reports have focused on the use of alternative natural medicines as potential therapeutic interventions in IBD patients with minimal side effects. While the use of alternative medicines may be effective in IBD patients that are refractory to corticosteroids or thiopurins, alternative treatment strategies are limited and require extensive clinical testing before being optimized for use in patients.

摘要

炎症性肠病(IBD)可分为两大类,溃疡性结肠炎(UC)和克罗恩病(CD)。虽然 IBD 的主要病因仍不清楚,但已经提出了许多针对 CD 和 UC 的干预和预防策略。许多报告都集中在使用替代天然药物作为潜在的治疗干预措施,以治疗 IBD 患者,这些药物的副作用极小。虽然替代药物在对皮质类固醇或硫嘌呤类药物难治的 IBD 患者中可能有效,但替代治疗策略有限,需要进行广泛的临床测试,然后才能针对患者进行优化。

相似文献

1
Alternative medicines as emerging therapies for inflammatory bowel diseases.
Int Rev Immunol. 2012 Feb;31(1):66-84. doi: 10.3109/08830185.2011.642909.
2
Complementary Therapies in Inflammatory Bowel Diseases.
Curr Gastroenterol Rep. 2016 Dec;18(12):62. doi: 10.1007/s11894-016-0537-6.
4
Resveratrol and inflammatory bowel disease.
Ann N Y Acad Sci. 2017 Sep;1403(1):38-47. doi: 10.1111/nyas.13426.
5
Cannabis use amongst patients with inflammatory bowel disease.
Eur J Gastroenterol Hepatol. 2011 Oct;23(10):891-6. doi: 10.1097/MEG.0b013e328349bb4c.
6
Complementary and Integrative Gastroenterology.
Med Clin North Am. 2017 Sep;101(5):943-954. doi: 10.1016/j.mcna.2017.04.009. Epub 2017 Jul 10.
7
Review article: complementary and alternative therapies for inflammatory bowel disease.
Aliment Pharmacol Ther. 2006 Feb 1;23(3):341-9. doi: 10.1111/j.1365-2036.2006.02761.x.
9
Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases.
J Crohns Colitis. 2015 Jan;9(1):86-106. doi: 10.1093/ecco-jcc/jju007. Epub 2014 Nov 28.

引用本文的文献

1
Potential of resveratrol in the treatment of systemic lupus erythematosus (Review).
Mol Med Rep. 2024 Oct;30(4). doi: 10.3892/mmr.2024.13306. Epub 2024 Aug 19.
2
Cross talk between the gut microbiome and host immune response in ulcerative colitis: nonpharmacological strategies to improve homeostasis.
Am J Physiol Gastrointest Liver Physiol. 2022 Dec 1;323(6):G554-G561. doi: 10.1152/ajpgi.00210.2022. Epub 2022 Oct 25.
4
Emerging role of protein modification in inflammatory bowel disease.
J Zhejiang Univ Sci B. 2022 Mar 15;23(3):173-188. doi: 10.1631/jzus.B2100114.
5
A Review of Four Practice Guidelines of Inflammatory Bowel Disease.
Cureus. 2021 Aug 3;13(8):e16859. doi: 10.7759/cureus.16859. eCollection 2021 Aug.
7
Effectiveness of C5a aptamers in a TNBS-induced colitis mouse model.
Exp Ther Med. 2017 Dec;14(6):6119-6124. doi: 10.3892/etm.2017.5277. Epub 2017 Oct 10.
8
Resveratrol Role in Autoimmune Disease-A Mini-Review.
Nutrients. 2017 Dec 1;9(12):1306. doi: 10.3390/nu9121306.
9
Role of microRNAs in resveratrol-mediated mitigation of colitis-associated tumorigenesis in Apc(Min/+) mice.
J Pharmacol Exp Ther. 2014 Jul;350(1):99-109. doi: 10.1124/jpet.114.213306. Epub 2014 May 9.
10
Nutritional modulators of ulcerative colitis: clinical efficacies and mechanistic view.
World J Gastroenterol. 2013 Feb 21;19(7):994-1004. doi: 10.3748/wjg.v19.i7.994.

本文引用的文献

1
Cells, cytokines and inflammatory bowel disease: a clinical perspective.
Expert Rev Gastroenterol Hepatol. 2011 Dec;5(6):703-16. doi: 10.1586/egh.11.74.
2
Emerging immunological targets in inflammatory bowel disease.
Curr Opin Pharmacol. 2011 Dec;11(6):640-5. doi: 10.1016/j.coph.2011.09.013. Epub 2011 Oct 12.
5
Protective effect of ellagic acid, a natural polyphenolic compound, in a murine model of Crohn's disease.
Biochem Pharmacol. 2011 Oct 1;82(7):737-45. doi: 10.1016/j.bcp.2011.06.043. Epub 2011 Jul 7.
6
N-Succinyl-chitosan systems for 5-aminosalicylic acid colon delivery: in vivo study with TNBS-induced colitis model in rats.
Int J Pharm. 2011 Sep 15;416(1):145-54. doi: 10.1016/j.ijpharm.2011.06.025. Epub 2011 Jun 23.
8
The efficacy of exclusive nutritional therapy in paediatric Crohn's disease, comparing fractionated oral vs. continuous enteral feeding.
Aliment Pharmacol Ther. 2011 Jun;33(12):1332-9. doi: 10.1111/j.1365-2036.2011.04662.x. Epub 2011 Apr 20.
9
Dietary aloin, aloesin, or aloe-gel exerts anti-inflammatory activity in a rat colitis model.
Life Sci. 2011 Mar 14;88(11-12):486-92. doi: 10.1016/j.lfs.2011.01.010. Epub 2011 Jan 26.
10
Review article: the role of non-biological drugs in refractory inflammatory bowel disease.
Aliment Pharmacol Ther. 2011 Feb;33(4):417-27. doi: 10.1111/j.1365-2036.2010.04541.x. Epub 2010 Dec 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验